"The voice for cancer physicians and their patients in Massachusetts."

FDA Approves pembrolizumab for HNSCC

11 Jun 2019 9:06 AM | Nathan Strunk (Administrator)

The U.S. Food and Drug Administration approved pembrolizumab (Keytruda; Merck) for the first-line treatment of patients with metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC). Read full press release. 

Massachusetts Society of Clinical Oncologists (c) 860 Winter Street, Waltham, MA. 02451

Waltham, MA. 02451

P.O. Box 549154, Waltham, MA, 02451
t: 781.434.7329 | f: 781.464.4896 |email: nstrunk@mms.org
Powered by Wild Apricot Membership Software